PVWM
TEVA icon

Point View Wealth Management’s Teva Pharmaceuticals TEVA Stock Holding History

Point View Wealth Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$444K Sell
46,052
-2,914
-6% -$27.9K 0.18% 170
2020
Q3 		$441K Sell
48,966
-722
-1% -$7.64K 0.21% 147
2020
Q2 		$613K Sell
49,688
-5,690
-10% -$64.4K 0.29% 109
2020
Q1 		$497K Buy
55,378
+6,035
+12% +$61.8K 0.27% 119
2019
Q4 		$484K Sell
49,343
-8,941
-15% -$79.8K 0.2% 154
2019
Q3 		$401K Sell
58,284
-16,514
-22% -$127K 0.18% 163
2019
Q2 		$690K Buy
74,798
+1,273
+2% +$15.3K 0.29% 117
2019
Q1 		$1.15M Buy
73,525
+453
+0.6% +$7.99K 0.51% 67
2018
Q4 		$1.13M Buy
73,072
+227
+0.3% +$4.65K 0.57% 58
2018
Q3 		$1.57M Buy
72,845
+1,242
+2% +$28.8K 0.7% 40
2018
Q2 		$1.74M Buy
71,603
+2,996
+4% +$61.1K 0.81% 33
2018
Q1 		$1.17M Buy
68,607
+23,593
+52% +$461K 0.56% 53
2017
Q4 		$853K Sell
45,014
-24,361
-35% -$366K 0.4% 86
2017
Q3 		$1.22M Buy
69,375
+24,969
+56% +$562K 0.59% 53
2017
Q2 		$1.48M Buy
44,406
+5,343
+14% +$165K 0.73% 31
2017
Q1 		$1.25M Buy
39,063
+13,247
+51% +$452K 0.65% 47
2016
Q4 		$936K Sell
25,816
-4,717
-15% -$188K 0.54% 60
2016
Q3 		$1.41M Sell
30,533
-258
-0.8% -$13.5K 0.83% 31
2016
Q2 		$1.55M Buy
30,791
+1,480
+5% +$78.8K 0.94% 25
2016
Q1 		$1.57M Buy
29,311
+1,620
+6% +$95.1K 1.01% 23
2015
Q4 		$1.82M Buy
27,691
+1,802
+7% +$111K 1.31% 11
2015
Q3 		$1.46M Sell
25,889
-96
-0.4% -$6.22K 1.17% 16
2015
Q2 		$1.54M Sell
25,985
-107
-0.4% -$6.6K 1.19% 17
2015
Q1 		$1.63M Buy
26,092
+2,208
+9% +$128K 1.26% 16
2014
Q4 		$1.37M Buy
23,884
+1,184
+5% +$66K 1.02% 26
2014
Q3 		$1.22M Buy
22,700
+2,070
+10% +$110K 1.04% 25
2014
Q2 		$1.08M Buy
20,630
+320
+2% +$16.4K 0.94% 26
2014
Q1 		$1.07M Buy
20,310
+1,815
+10% +$83.9K 0.98% 24
2013
Q4 		$741K Buy
+18,495
New +$728K 0.7% 48

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

Point View Wealth Management's TEVA Position: Q4 2020 in Review

Point View Wealth Management reduced its Teva Pharmaceuticals (TEVA) stake by 6% in Q4 2020, selling an estimated $27.9K and leaving 46,052 shares worth $444K. The position accounts for 0.18% of the portfolio, ranked #170.

Point View Wealth Management first reported a position in TEVA in Q4 2013 and has held it in 29 quarters since. The position peaked at $1.82M in Q4 2015. 450 funds tracked by Wall St. Rank hold TEVA as of Q4 2020.

  • Point View Wealth Management held 46,052 shares of Teva Pharmaceuticals worth $444K as of Q4 2020.
  • Point View Wealth Management sold 2,914 Teva Pharmaceuticals shares in Q4 2020, an estimated $27.9K.
  • Teva Pharmaceuticals made up 0.18% of Point View Wealth Management's portfolio in Q4 2020, its #170 holding.
  • Point View Wealth Management first reported a position in Teva Pharmaceuticals in Q4 2013 and has held it in 29 quarters since.
  • Point View Wealth Management's Teva Pharmaceuticals position peaked at $1.82M in Q4 2015.
  • 450 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2020.

Based on Point View Wealth Management's 13F filing for Q4 2020, filed 8 Feb 2021.